JP2005538129A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538129A5
JP2005538129A5 JP2004527183A JP2004527183A JP2005538129A5 JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5 JP 2004527183 A JP2004527183 A JP 2004527183A JP 2004527183 A JP2004527183 A JP 2004527183A JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5
Authority
JP
Japan
Prior art keywords
cpt
capecitabine
topotecan
adriamycin
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004527183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003388 external-priority patent/WO2004014386A1/en
Publication of JP2005538129A publication Critical patent/JP2005538129A/ja
Publication of JP2005538129A5 publication Critical patent/JP2005538129A5/ja
Withdrawn legal-status Critical Current

Links

JP2004527183A 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ Withdrawn JP2005538129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11
PCT/IB2003/003388 WO2004014386A1 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Publications (2)

Publication Number Publication Date
JP2005538129A JP2005538129A (ja) 2005-12-15
JP2005538129A5 true JP2005538129A5 (enExample) 2006-09-14

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527183A Withdrawn JP2005538129A (ja) 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ

Country Status (17)

Country Link
US (2) US20040067942A1 (enExample)
EP (1) EP1549320A1 (enExample)
JP (1) JP2005538129A (enExample)
CN (1) CN1674908A (enExample)
AR (1) AR040792A1 (enExample)
AU (1) AU2003249450A1 (enExample)
BR (1) BR0313470A (enExample)
CA (1) CA2494270A1 (enExample)
IL (1) IL166423A0 (enExample)
MX (1) MXPA05001430A (enExample)
NO (1) NO20051170L (enExample)
PA (1) PA8578001A1 (enExample)
PE (1) PE20040990A1 (enExample)
PL (1) PL375414A1 (enExample)
RU (1) RU2005102836A (enExample)
TW (1) TW200404532A (enExample)
WO (1) WO2004014386A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) * 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
JP2008501652A (ja) * 2004-06-03 2008-01-24 エフ.ホフマン−ラ ロシュ アーゲー ゲムシタビン及びegfrインヒビターによる治療
RU2006146625A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
MXPA06013952A (es) * 2004-06-04 2007-02-08 Smithkline Beecham Cork Ltd Metodo para el tratamiento de cancer.
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
CN103596592A (zh) * 2011-05-06 2014-02-19 梅里麦克制药股份有限公司 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
US20210275518A1 (en) * 2020-03-06 2021-09-09 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of disorders
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药(上海)有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors

Similar Documents

Publication Publication Date Title
Carmichael The role of gemcitabine in the treatment of other tumours
Tomek et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments
RU2008118144A (ru) Комбинации иммуномодулирующих олигоодезоксинуклеотидов и способы их применения
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
JP2012523435A5 (enExample)
RU2011145773A (ru) Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов
JP2004525950A5 (enExample)
RU2012156958A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
JP2010514787A5 (enExample)
JP2017025090A5 (enExample)
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2011522773A5 (enExample)
Grünwald et al. Development of the epidermal growth factor receptor inhibitor Tarceva™(OSI-774)
JP2006500346A5 (enExample)
RU2006122350A (ru) Комбинированная химиотерапия
NO20033910D0 (no) Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin
AR040792A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
JP2023533937A5 (enExample)
JP2006502132A5 (enExample)
Punt New drugs in the treatment of colorectal carcinoma
JP2007277240A5 (enExample)
RU2008148597A (ru) Фармацевтические комбинации
JP2003526667A5 (enExample)
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor